SpringWorks Therapeutics Reports Full Enrollment Of Phase 2 Trial Evaluating Nirogacestat In Patients With Ovarian Granulosa Cell Tumors
Portfolio Pulse from Benzinga Newsdesk
SpringWorks Therapeutics has fully enrolled its Phase 2 trial evaluating Nirogacestat in patients with ovarian granulosa cell tumors (OvGCT). Initial data from the trial is expected to be reported in 2024. OvGCT accounts for 5% of all ovarian cancers and 70% of ovarian sex cord tumors.
May 30, 2023 | 10:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SpringWorks Therapeutics' stock may be positively impacted by the full enrollment of its Phase 2 trial for Nirogacestat in OvGCT patients.
The full enrollment of the Phase 2 trial is a significant milestone for SpringWorks Therapeutics, as it indicates progress in the development of Nirogacestat. This news may be seen as positive by investors, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100